Efficacy and tolerability of trandolapril in mild to moderate hypertension - A double blind comparative clinical trial with enalapril in Indian population

Pinakini K. Shankar, Sudha Vidyasagar, Sachidananda Adiga, M. U.R. Naidu, Usha Rani P, Dayasagar Rao, K. L. Bairy, Sreekumaran Nair, B. Jayaprakash, U. Shashikiran, Mukhyapranaprabhu

Research output: Contribution to journalArticle

Abstract

Several large scale clinical trials have demonstrated that angiotensin converting enzyme inhibitors offer cardiovascular and renal protection independent of their effects on systolic BP. Trandolapril is a new angiotensin converting enzyme inhibitor approved for the treatment of hypertension. The potential advantages of this drug are long duration of action and better tolerability. The objective of the study was to compare the efficacy and tolerability of trandolapril with that of enalapril in mild to moderate hypertension in Indian population. In this double blind, multicentric, parallel comparative clinical study, 120 patients with mild to moderate hypertension were randomly assigned to receive trandolapril 2 mg or enalapril 5 mg once daily for 8 weeks. The attainment of sitting diastolic blood pressure <90 mmHg at the end of 8th week was considered as primary outcome measure and attainment of diastolic blood pressure <90 mmHg or reduction of at least 10 mmHg diastolic blood pressure compared to baseline at any visit was considered as secondary outcome measures. 98.4% patients treated with trandolapril and 92.6% patients treated with enalapril fulfilled the primary outcome measure. 54, 72 and 62% patients on trandolapril and 52, 61 & 64% patients on enalapril fulfilled secondary outcome measure at the end of 2nd, 4th and 8th week respectively. Also trandolapril was better tolerated than enalapril with no significant abnormality in lab parameters.

Original languageEnglish
Pages (from-to)421-426
Number of pages6
JournalIndian Journal of Physiology and Pharmacology
Volume50
Issue number4
Publication statusPublished - 01-10-2006

Fingerprint

trandolapril
Enalapril
Clinical Trials
Blood Pressure
Hypertension
Outcome Assessment (Health Care)
Population
Angiotensin-Converting Enzyme Inhibitors

All Science Journal Classification (ASJC) codes

  • Physiology
  • Pharmacology
  • Physiology (medical)

Cite this

Shankar, Pinakini K. ; Vidyasagar, Sudha ; Adiga, Sachidananda ; Naidu, M. U.R. ; Rani P, Usha ; Rao, Dayasagar ; Bairy, K. L. ; Nair, Sreekumaran ; Jayaprakash, B. ; Shashikiran, U. ; Mukhyapranaprabhu. / Efficacy and tolerability of trandolapril in mild to moderate hypertension - A double blind comparative clinical trial with enalapril in Indian population. In: Indian Journal of Physiology and Pharmacology. 2006 ; Vol. 50, No. 4. pp. 421-426.
@article{2579098b908540b3bacbb1ca0ad27471,
title = "Efficacy and tolerability of trandolapril in mild to moderate hypertension - A double blind comparative clinical trial with enalapril in Indian population",
abstract = "Several large scale clinical trials have demonstrated that angiotensin converting enzyme inhibitors offer cardiovascular and renal protection independent of their effects on systolic BP. Trandolapril is a new angiotensin converting enzyme inhibitor approved for the treatment of hypertension. The potential advantages of this drug are long duration of action and better tolerability. The objective of the study was to compare the efficacy and tolerability of trandolapril with that of enalapril in mild to moderate hypertension in Indian population. In this double blind, multicentric, parallel comparative clinical study, 120 patients with mild to moderate hypertension were randomly assigned to receive trandolapril 2 mg or enalapril 5 mg once daily for 8 weeks. The attainment of sitting diastolic blood pressure <90 mmHg at the end of 8th week was considered as primary outcome measure and attainment of diastolic blood pressure <90 mmHg or reduction of at least 10 mmHg diastolic blood pressure compared to baseline at any visit was considered as secondary outcome measures. 98.4{\%} patients treated with trandolapril and 92.6{\%} patients treated with enalapril fulfilled the primary outcome measure. 54, 72 and 62{\%} patients on trandolapril and 52, 61 & 64{\%} patients on enalapril fulfilled secondary outcome measure at the end of 2nd, 4th and 8th week respectively. Also trandolapril was better tolerated than enalapril with no significant abnormality in lab parameters.",
author = "Shankar, {Pinakini K.} and Sudha Vidyasagar and Sachidananda Adiga and Naidu, {M. U.R.} and {Rani P}, Usha and Dayasagar Rao and Bairy, {K. L.} and Sreekumaran Nair and B. Jayaprakash and U. Shashikiran and Mukhyapranaprabhu",
year = "2006",
month = "10",
day = "1",
language = "English",
volume = "50",
pages = "421--426",
journal = "Indian Journal of Physiology and Pharmacology",
issn = "0019-5499",
publisher = "Association of Physiologists and Pharmacologists of India",
number = "4",

}

Efficacy and tolerability of trandolapril in mild to moderate hypertension - A double blind comparative clinical trial with enalapril in Indian population. / Shankar, Pinakini K.; Vidyasagar, Sudha; Adiga, Sachidananda; Naidu, M. U.R.; Rani P, Usha; Rao, Dayasagar; Bairy, K. L.; Nair, Sreekumaran; Jayaprakash, B.; Shashikiran, U.; Mukhyapranaprabhu.

In: Indian Journal of Physiology and Pharmacology, Vol. 50, No. 4, 01.10.2006, p. 421-426.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and tolerability of trandolapril in mild to moderate hypertension - A double blind comparative clinical trial with enalapril in Indian population

AU - Shankar, Pinakini K.

AU - Vidyasagar, Sudha

AU - Adiga, Sachidananda

AU - Naidu, M. U.R.

AU - Rani P, Usha

AU - Rao, Dayasagar

AU - Bairy, K. L.

AU - Nair, Sreekumaran

AU - Jayaprakash, B.

AU - Shashikiran, U.

AU - Mukhyapranaprabhu,

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Several large scale clinical trials have demonstrated that angiotensin converting enzyme inhibitors offer cardiovascular and renal protection independent of their effects on systolic BP. Trandolapril is a new angiotensin converting enzyme inhibitor approved for the treatment of hypertension. The potential advantages of this drug are long duration of action and better tolerability. The objective of the study was to compare the efficacy and tolerability of trandolapril with that of enalapril in mild to moderate hypertension in Indian population. In this double blind, multicentric, parallel comparative clinical study, 120 patients with mild to moderate hypertension were randomly assigned to receive trandolapril 2 mg or enalapril 5 mg once daily for 8 weeks. The attainment of sitting diastolic blood pressure <90 mmHg at the end of 8th week was considered as primary outcome measure and attainment of diastolic blood pressure <90 mmHg or reduction of at least 10 mmHg diastolic blood pressure compared to baseline at any visit was considered as secondary outcome measures. 98.4% patients treated with trandolapril and 92.6% patients treated with enalapril fulfilled the primary outcome measure. 54, 72 and 62% patients on trandolapril and 52, 61 & 64% patients on enalapril fulfilled secondary outcome measure at the end of 2nd, 4th and 8th week respectively. Also trandolapril was better tolerated than enalapril with no significant abnormality in lab parameters.

AB - Several large scale clinical trials have demonstrated that angiotensin converting enzyme inhibitors offer cardiovascular and renal protection independent of their effects on systolic BP. Trandolapril is a new angiotensin converting enzyme inhibitor approved for the treatment of hypertension. The potential advantages of this drug are long duration of action and better tolerability. The objective of the study was to compare the efficacy and tolerability of trandolapril with that of enalapril in mild to moderate hypertension in Indian population. In this double blind, multicentric, parallel comparative clinical study, 120 patients with mild to moderate hypertension were randomly assigned to receive trandolapril 2 mg or enalapril 5 mg once daily for 8 weeks. The attainment of sitting diastolic blood pressure <90 mmHg at the end of 8th week was considered as primary outcome measure and attainment of diastolic blood pressure <90 mmHg or reduction of at least 10 mmHg diastolic blood pressure compared to baseline at any visit was considered as secondary outcome measures. 98.4% patients treated with trandolapril and 92.6% patients treated with enalapril fulfilled the primary outcome measure. 54, 72 and 62% patients on trandolapril and 52, 61 & 64% patients on enalapril fulfilled secondary outcome measure at the end of 2nd, 4th and 8th week respectively. Also trandolapril was better tolerated than enalapril with no significant abnormality in lab parameters.

UR - http://www.scopus.com/inward/record.url?scp=33751199637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751199637&partnerID=8YFLogxK

M3 - Article

C2 - 17402274

AN - SCOPUS:33751199637

VL - 50

SP - 421

EP - 426

JO - Indian Journal of Physiology and Pharmacology

JF - Indian Journal of Physiology and Pharmacology

SN - 0019-5499

IS - 4

ER -